ES2188802T3 - Vectores viricos de replicacion condicional y su uso. - Google Patents

Vectores viricos de replicacion condicional y su uso.

Info

Publication number
ES2188802T3
ES2188802T3 ES96942083T ES96942083T ES2188802T3 ES 2188802 T3 ES2188802 T3 ES 2188802T3 ES 96942083 T ES96942083 T ES 96942083T ES 96942083 T ES96942083 T ES 96942083T ES 2188802 T3 ES2188802 T3 ES 2188802T3
Authority
ES
Spain
Prior art keywords
viric
vector
vectors
replication
procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96942083T
Other languages
English (en)
Inventor
Boro Dropulic
Paula M Pitha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of ES2188802T3 publication Critical patent/ES2188802T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE UN VECTOR VIRICO DE REPLICACION CONDICIONADA, PROCEDIMIENTOS PARA PREPARAR, MODIFICAR, PROPAGAR, ENCAPSULAR DE FORMA SELECTIVA Y UTILIZAR DICHO VECTOR, MOLECULAS AISLADAS DE SECUENCIAS DE NUCLEOTIDOS Y DE AMINOACIDOS ESPECIFICADAS RELACIONADAS CON DICHOS VECTORES, UNA COMPOSICION FARMACEUTICA Y UNA CELULA HUESPED QUE INCLUYEN DICHO VECTOR, Y EL USO DE DICHA CELULA HUESPED PARA SELECCIONAR FARMACOS. LOS PROCEDIMIENTOS INCLUYEN EL TRATAMIENTO PROFILACTICO Y TERAPEUTICO DE UNA INFECCION VIRICA, EN ESPECIAL UNA INFECCION POR VIH, Y POR TANTO TAMBIEN ESTAN DIRIGIDOS A VACUNAS VIRICAS Y AL TRATAMIENTO DEL CANCER, EN PARTICULAR DEL CANCER DE ETIOLOGIA VIRICA. OTROS PROCEDIMIENTOS INCLUYEN EL USO DE DICHOS VECTORES VIRICOS DE REPLICACION CONDICIONADA EN TERAPIA GENICA Y OTRAS APLICACIONES.
ES96942083T 1995-11-28 1996-11-27 Vectores viricos de replicacion condicional y su uso. Expired - Lifetime ES2188802T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56345995A 1995-11-28 1995-11-28

Publications (1)

Publication Number Publication Date
ES2188802T3 true ES2188802T3 (es) 2003-07-01

Family

ID=24250568

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96942083T Expired - Lifetime ES2188802T3 (es) 1995-11-28 1996-11-27 Vectores viricos de replicacion condicional y su uso.

Country Status (18)

Country Link
EP (2) EP0871757B1 (es)
JP (2) JP2000503527A (es)
KR (1) KR100537458B1 (es)
CN (3) CN1651577A (es)
AT (2) ATE234362T1 (es)
AU (3) AU1124997A (es)
BR (1) BR9612574A (es)
CA (1) CA2236868C (es)
CZ (1) CZ294170B6 (es)
DE (2) DE69638120D1 (es)
DK (1) DK0871757T3 (es)
ES (1) ES2188802T3 (es)
IL (2) IL124636A0 (es)
NO (1) NO329619B1 (es)
NZ (1) NZ324157A (es)
PT (1) PT871757E (es)
RU (1) RU2270250C2 (es)
WO (1) WO1997020060A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037669A4 (en) * 1997-12-12 2003-04-02 Cell Genesys Inc THERAPEUTIC USE OF LENTIVIRAL VECTORS
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
NZ525283A (en) * 2000-09-22 2008-06-30 Virxsys Corp Conditionally replicating vectors, methods for their production and use
US20030026791A1 (en) * 2001-03-27 2003-02-06 Laurent Humeau Conditionally replicating vectors for inhibiting viral infections
HRP20180184T1 (hr) 2007-12-11 2018-04-06 The University Of North Carolina At Chapel Hill Retrovirusni vektori s modificiranim polipurinskim nizom
EP3520813B1 (en) * 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
SG11201705988UA (en) * 2015-02-24 2017-08-30 Bioatla Llc Conditionally active biological proteins
CN104711294A (zh) * 2015-04-02 2015-06-17 扬州大学 一种基于禽网状内皮组织增生症病毒ltr的真核表达线性化载体的构建方法及应用
GB2543730A (en) * 2015-05-26 2017-05-03 Andrzejewski Slawomir Use of replication competent vector to eradicate viral latency presented on human immunodeficiency virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
AU680921B2 (en) * 1993-05-17 1997-08-14 Regents Of The University Of California, The Ribozyme gene therapy for HIV infection and AIDS
DE69534864T2 (de) * 1994-01-05 2007-02-22 Gene Shears Pty. Ltd. Ribozyme gegen eine HIV Tat Sequenz
WO1995030755A1 (en) * 1994-05-10 1995-11-16 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof

Also Published As

Publication number Publication date
CN1207775A (zh) 1999-02-10
JP2000503527A (ja) 2000-03-28
NO329619B1 (no) 2010-11-22
AU2004200663B2 (en) 2007-07-05
DK0871757T3 (da) 2003-07-14
PT871757E (pt) 2003-08-29
CN1651577A (zh) 2005-08-10
EP1380650B1 (en) 2010-01-20
IL124636A0 (en) 1998-12-06
IL124636A (en) 2009-12-24
WO1997020060A1 (en) 1997-06-05
DE69638120D1 (de) 2010-03-11
EP1380650A1 (en) 2004-01-14
KR100537458B1 (ko) 2008-09-08
KR19990071728A (ko) 1999-09-27
RU2270250C2 (ru) 2006-02-20
CN1940076A (zh) 2007-04-04
CZ294170B6 (cs) 2004-10-13
NO982418L (no) 1998-07-27
AU1124997A (en) 1998-06-19
JP2007014341A (ja) 2007-01-25
ATE234362T1 (de) 2003-03-15
AU767620B2 (en) 2003-11-20
AU2004200663A1 (en) 2004-04-08
BR9612574A (pt) 2000-04-25
DE69626681T2 (de) 2004-02-12
ATE455858T1 (de) 2010-02-15
DE69626681D1 (de) 2003-04-17
CA2236868C (en) 2014-01-21
NO982418D0 (no) 1998-05-27
EP0871757A1 (en) 1998-10-21
CZ162498A3 (cs) 1998-12-16
NZ324157A (en) 2000-10-27
CN100390291C (zh) 2008-05-28
CA2236868A1 (en) 1997-06-05
EP0871757B1 (en) 2003-03-12
AU1000001A (en) 2001-05-17
JP4384146B2 (ja) 2009-12-16
HK1060152A1 (en) 2004-07-30

Similar Documents

Publication Publication Date Title
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
ATE466084T1 (de) Hla-a24-restringiertes krebsantigenpeptid
ES2097878T3 (es) Fijacion de p53 sobre el adn mediante una secuencia especifica.
BRPI0010612B8 (pt) vacinas
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
AR020134A1 (es) Antigenos inmunologicos contra el virus herpes simplex y metodos para el uso de los mismos
AR032743A1 (es) Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
NO953699D0 (no) Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav
ATE282434T1 (de) Eine zusammensetzung enthaltend eine detergenz und einen ein tumorsuppressorgen kodierenden, adenoviralen vektor
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
MXPA03001634A (es) Polipeptido tumoral cripto.
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
ES2188802T3 (es) Vectores viricos de replicacion condicional y su uso.
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
ES2160601T3 (es) Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.
ES2163795T3 (es) Composicion farmaceutica contra los tumores e infecciones por papilomavirus.
ES2139596T3 (es) Procedimiento para el diagnostico in vitro de anomalias cromosomicas relacionadas con la enfermedad cmt1a.
NO984052D0 (no) Rekombinante, adenovirale vektorer for human tumorgenterapi
MX2023007229A (es) Constructo de arn.
ES2061521T3 (es) Proteinas con actividad glutation-s-transferasa, secuencias de adn, anticuerpos, poxvirus y medicamentos para la prevencion de la equistosomiasis.